Boehringer Ingelheim, a research─driven pharmaceutical company, announced that in the phase III INBUILD trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed

COVID-19 New research shows that the COVID-19 coronavirus is stable for hours to days in aerosols and on surface. This study was carried out by the National Institute of Allergy and Infectious Diseases (NIAID) and...

As the landscape of philanthropy changes following the COVID-19 pandemic, this commentary considers the future of endowed chairs in academic medicine in the light of articles by Thorndyke and colleagues and by Chin-Hong...

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been performing well in ongoing clinical studies investigating its...